c-MET (D1228A)

MET · Variant type: point · HGVS: p.D1228A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	91.3%	8.7%	88.97
2	Tivozanib	70.5%	29.5%	92.42
3	Pacritinib	68.5%	31.5%	88.64
4	Repotrectinib	62.0%	38.0%	84.21
5	Defactinib	54.6%	45.4%	92.68
6	Neratinib	48.0%	52.0%	93.18
7	Canertinib	42.4%	57.6%	96.49
8	Capmatinib	41.4%	58.6%	99.75
9	Tepotinib	35.6%	64.4%	99.75
10	Selpercatinib	35.4%	64.6%	96.72
11	Sunitinib	32.6%	67.4%	91.73
12	Fedratinib	23.4%	76.6%	96.21
13	Entrectinib	19.3%	80.7%	93.69
14	Vandetanib	18.4%	81.6%	95.74
15	Umbralisib	16.7%	83.3%	98.74
16	Abemaciclib	15.2%	84.8%	91.48
17	Avapritinib	14.7%	85.3%	97.73
18	Erlotinib	13.8%	86.2%	99.75
19	Ripretinib	11.5%	88.5%	92.95
20	Sorafenib	8.9%	91.1%	96.72
21	Apatinib	8.7%	91.3%	97.73
22	Infigratinib	8.6%	91.4%	98.24
23	Pexidartinib	8.6%	91.4%	99.49
24	Idelalisib	7.5%	92.5%	100.00
25	Palbociclib	7.0%	93.0%	98.75

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	91.3%	—	—
Tivozanib	70.5%	—	—
Pacritinib	68.5%	—	—
Repotrectinib	62.0%	—	—
Defactinib	54.6%	—	—
Neratinib	48.0%	—	—
Canertinib	42.4%	—	—
Capmatinib	41.4%	—	—
Tepotinib	35.6%	—	—
Selpercatinib	35.4%	—	—
Sunitinib	32.6%	—	—
Fedratinib	23.4%	—	—
Entrectinib	19.3%	—	—
Vandetanib	18.4%	—	—
Umbralisib	16.7%	—	—
Abemaciclib	15.2%	—	—
Avapritinib	14.7%	—	—
Erlotinib	13.8%	—	—
Ripretinib	11.5%	—	—
Sorafenib	8.9%	—	—
Apatinib	8.7%	—	—
Infigratinib	8.6%	—	—
Pexidartinib	8.6%	—	—
Idelalisib	7.5%	—	—
Palbociclib	7.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms